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Abstract: G-protein-coupled receptors (GPCRs), which are encoded by >300 genes in the human genome, are by far the largest class of 
targets for modern drugs. These macromolecules display inherent adaptability of function, which is partly due to the production of differ-
ent forms of the receptor protein. These are commonly called ‘isoforms’ or ‘splice variants’ denoting the molecular process of their pro-
duction/assembly. Not all GPCRs are expressed as splice variants, but certain subclasses of 5-HT receptors are for example, the 5-HT4
and 5-HT7 receptors. There are at least 11 human 5-HT4 and three h5-HT7 receptor splice variants. This review describes their discover-
ies, nomenclature and structures. The discovery that particular splice variants are tissue specific (or prominent) has highlighted their po-
tential as future drug targets. In particular, this review examines the functional relevance of different 5-HT4 and 5-HT7 receptor splice 
variants. Examples are given to illustrate that splice variants have differential modulatory influences on signalling processes. Differences 
in agonist potency and efficacies and also differences in desensitisation rates to 5-HT occur with both 5-HT4 and 5-HT7 receptor splice 
variants. The known and candidate signalling systems that allow for splice variant specific responses include GPCR interacting proteins 
(GIPs) and GPCR receptor kinases (GRKs) which are examined. Finally, the relevance of 5-HT receptor splice variants to clinical medi-
cine and to the pharmaceutical industry is discussed.
Key Words: Serotonin receptors, GPCR receptor isoforms, GPCR receptor splice variants, GPCR interacting proteins, desensitisation, func-
tional intestinal disorders, irritable bowel syndrome. 
INTRODUCTION 
  G-protein-coupled receptors (GPCRs) are by far the largest 
class of targets for modern drugs. These macromolecules are en-
coded by >300 genes in the human genome. Once formed, they are 
transported and embedded in the cell-surface, where they take on 
their functions of detecting and responding to a diverse array of 
ligands. Numerous diseases and disorders have been linked to mu-
tations and polymorphisms in GPCRs and in their natural states 
these receptors are the targets of an increasingly large number of 
therapeutic agents. It has been estimated that 50% of all modern 
drugs and almost one-quarter of the top 200 best-selling drugs 
in 2000 modulate GPCR activity (see [32] for review). Studies 
into GPCR splice variants or isoforms is a new research area that 
opens the possibilities to further refine safety margins of thera-
peutic drugs. 
  A general property of GPCRs is that they have inherent adapt-
ability built into their function, which is partly due to the produc-
tion of different forms of the receptor protein. Thus, different prod-
ucts can be generated from a single GPCR gene by the combination 
of alternative forms of particular exons. This process is referred to 
as ‘alternative splicing’ and translated products are called ‘splice 
variants’ or more commonly ‘isoforms’ (see Fig. 1). Over 70% of 
multi-exon genes expressed in humans are alternatively spliced to 
form various splice variants and the proteins involved in cellular 
communication are common amongst examples [41]. The discovery 
that particular splice variants are tissue specific (or prominent) has 
highlighted their potential as future drug targets. Therefore, just as 
the discovery of different receptor subgroups opened up vast oppor-
tunities to develop new drug treatments, the discovery of splice 
variants promises to further expand and refine these opportunities. 
Examples are to be found with prostaglandin EP3 receptors, which 
are subject to splice variance at the C-terminus and, to date, 10 
splice variants have been identified across species, six of these be-
ing expressed in man. In addition, there is evidence for a splice 
variant form of EP1 receptor that lacks the highly conserved seventh 
transmembrane domain (TM). Amongst adrenoceptors, four splice 
variants of the 1A-AR have been reported as well as variants of the 
3-AR. Of the serotonin (5-hydroxytryptamine, 5-HT) receptors, the 
5-HT4 and 5-HT7 receptors in particular are noteworthy for the 
production of several splice variants [40]. 
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Fig. (1). Methods of isoform or splice variant generation. RNA editing from 
adenosine deamination to form inosine which is read as guanosine and so 
codes for different amino acids. Alternatively if additional splice junctions 
are present (e.g. at * but also at the ends of exons depicted by boxes), exons 
can be incorporated or removed (drawn) resulting in different length 
mRNAs and so different proteins.
  Several questions arise when considering the purpose of these 
GPCR splice variants. Are they expressed in specific tissues? Do 
they modulate signalling processes in different fashions? If so, 
could they act as potential therapeutic targets? Here we will discuss 
these questions in relation to serotonin receptor splice variants with 
an emphasis on the distribution of 5-HT4 and 5-HT7 receptor splice 
variants and their potential as therapeutic targets. We will empha-
sise the neuropharmacological aspects. However, 5-HT receptors 
are widely distributed, so it is important to note that substantial 
information has been acquired about their splice variants by study-
ing peripheral tissues. Although 5-HT receptor splice variants are 
localised to nerve elements in many tissues, others are found in 
effector cells, such as smooth muscle. It is also important to note, 
that much of our knowledge about the function of splice variants 
comes from cell culture techniques. Although these can be criti-
cised for being artificial and minimalist, they are the only practical 
way of studying individual splice variants, because most native 
cells express a mixture. In this review we first outline a brief com-
mentary on the functions and classification system of 5-HT recep-
tors. We will also refer to some excellent and extensive reviews on 
other aspects of the subject which are not covered in this paper. For 
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ceptors are described [38] and the distribution and function of 5-
HT7 receptors has been reviewed [48,73]. There are also extensive 
reviews of the medicinal chemistry and pharmacology of 5-HT4
agonists and antagonists [46] and of 5-HT7 receptor ligands [33]. In 
addition, the clinical relevance of 5-HT receptors in pathophysi-
ological conditions and their targeting with therapeutic drugs is 
covered [29].  
5-HT 
  5-HT has diverse physiological effects and broadly these en-
compass regulation of the cardiovascular, digestive and central 
nervous systems. Mammalian physiologists had known since the 
1800s that a vasoconstrictor substance was formed when blood was 
allowed to clot. In 1948, Rapport named the serum vasoconstrictor 
‘serotonin’ and a year later he discovered that the active substance 
was 5-hydroxytryptamine. 5-HT is widely distributed in nature, 
occurring in both plants and animals. In mammals the largest 
amount of 5-HT is present along the length of the gastrointestinal 
tract (60-90%), mainly in enterochromaffin (EC) cells of the mu-
cosal layer. The remainder occurs in the enteric nervous system 
with significant distribution in the brain and spinal cord, the heart 
and adrenocortical cells. 5-HT is synthesised from tryptophan in 
these sites, but the 5-HT content of platelets is acquired mainly 
from EC cells. It is now recognised that disturbances in the levels of 
5-HT and/or the densities of its receptors contributes to the patho-
genesis of many clinical conditions. Some examples are the carci-
noid syndrome and gastrointestinal motility disorders in the periph-
ery, and migraine, depression, anxiety, schizophrenia, obsessive 
compulsive disorders, eating disorders and the serotonin syndrome 
centrally. 
5-HT RECEPTORS 
  The physiological and pathophysiological effects of 5-HT are 
mediated by at least 14 different receptor subtypes [2,37]. This 
relatively large number is attributed to the long evolutionary history 
of the 5-HT signalling system, which predates the separation of 
vertebrates and invertebrates, some 600 million years ago. Conse-
quently, there has been abundant time for gene duplications, fol-
lowed by mutations and sequence shifts to form the different genes 
encoding for the different subtypes. It has been speculated that the 
ancestral 5-HT receptors functioned to facilitate cell to cell connec-
tions and to promote growth and differentiation. This diversified to 
the level of complexity now apparent in the mammalian brain (for 
reviews, see [5,8,18,71]).  
  All mammalian 5-HT receptors are members of the GPCR su-
perfamily of membrane-bound receptors (also called metabotropic 
receptors) with the exception of the 5-HT3 receptor which is an ion 
channel. These are classified into seven distinct classes, or families, 
according to their structure, pharmacological properties and pre-
ferred effector mechanisms according to the current IUPHAR ap-
pellation of 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-ht5, 5-HT6 and 5-HT7.
Some of these classes include multiple receptors, which share simi-
lar structural and effector properties, but display very different op-
erational profiles. The lower case character denotes that the class 
concerned has not been ascribed functional roles although structural 
and transduction information is known. The 5-HT1 receptor class 
comprises five different receptors; 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e
and 5-HT1F which couple preferentially to Gi/Go to inhibit cAMP 
formation. The 5-HT2 receptor class comprises three receptors; 
5-HT2A, 5-HT2B and 5-HT2C that couple preferentially to Gq/G11 to 
increase the hydrolysis of inositol phosphates and elevate cytosolic 
[Ca
2+]. Selective antagonists for each receptor are now becoming 
available. The 5-HT3 receptor is a pentameric ion channel that ap-
pears to be located exclusively in neuronal tissue where it mediates 
fast depolarization. 5-HT4, 5-HT6 and 5-HT7 receptors all couple 
preferentially to Gs and promote cAMP formation, while the 5-ht5,
receptor is able to couple to several signalling pathways including 
Gi/Go [40]. Numerous selective 5-HT4 receptor agonists and an-
tagonists are now available and selective antagonists for the 5-HT7
receptor and putative 5-HT6 receptor antagonists have also recently 
been reported. Many therapeutic drugs target 5-HT receptors, with 
notable examples being: the anxiolytic buspirone (5-HT1A agonist), 
the antimigraine drug sumatriptan (5-HT1B/D agonist), the antide-
pressant mianserine (5-HT2A/C antagonist), the antiemetic ondanse-
tron (5-HT3 antagonist), and tegaserod (5-HT4 partial agonist), 
which has been used to treat the constipation-predominant form of 
irritable bowel syndrome (IBS).  
5-HT RECEPTORS WITH ISOFORMS 
 The  5-HT1 receptor family (5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e and 
5-HT1F) are intronless so do not form splice variants [18,68]. Al-
though the 5-HT2 receptor family (5-HT2A, 5-HT2B and 5-HT2C)
contains introns, the splice variants formed by alternative splicing 
produce truncated non-functional proteins. However, the 5-HT2C
receptor forms isoforms through RNA editing involving the enzyme 
family of adenosine deaminases that act on RNA (Fig. 1) where 
agonist potency, activation of phospholipase C and selectivity of G 
protein coupling are generally reduced (for a review see [67]). The 
5-HT4, 5-ht6 and 5-HT7 receptors contain introns [18,68] and it has 
been demonstrated that the well characterised 5-HT4 and 5-HT7
receptors form multiple splice variants. These are the subject of this 
review. 
Human 5-HT4 Receptor Splice Variants 
  There are at least 11 human 5-HT4 receptor splice variants. The 
major relevance of this recent knowledge is that differences in the 
tissue distribution and function of 5-HT4 splice variants could po-
tentially be used as a basis for new drug development. For instance, 
discovery of heart-selective drugs is achievable if the heart is found 
to express a 5-HT4 splice variant as the therapeutic target that is 
unique to the heart or more prevalent to the heart than other organs. 
 The  5-HT4 receptor present in the human atrium was the first to 
be cloned and characterised. Following its discovery in 1997 and 
naming as h5-HT4(a) [14]; several other splice variants have been 
cloned: h5-HT4(b) [15,72], two different h5-HT4(c) splice variants 
[13,15], h5-HT4(d) [15], h5-HT4(e) [13], h5-HT4(f) [13], h5-HT4(g)
[13,24] (formerly called (e) [58] see [46]), h5-HT4(i) [20], h5-HT4(h)
[13] the only example of an internal splice variant insert occurring 
in the 2
nd extracellular loop, and h5-HT4(n) [74] (Fig. 2A). From the 
viewpoint of drug discovery, the tissue distribution of these human 
splice variants shows a degree of specificity (see [46] for review). 
In addition, cellular studies show that desensitisation rates of 5-HT4
receptor splice variants depends upon the GPCR kinases (GRK) 
present [10] and the splice variant [64]. 
 The  h5-HT4(b) is dominant in most tissues and the h5-HT4(a) is 
also common, so opportunities for drug discovery need to take ad-
vantage of other tissue-specific splice variants. Table 1 summarises 
the current state of knowledge. Focussing on the atrial tissue of the 
heart, it can be seen that it is relatively well endowed with splice 
variants compared to the kidney and bladder. Also, it expresses the 
(n) splice variant, as does the brain and oesophagus, but this is ab-
sent from the kidney, bladder, stomach, ileum and colon. The cur-
rent state of knowledge shows the human small intestine and colon 
also express h5-HT4(d) and that this is not found in other tissues 
[13,15,56]. Many of the other splice variants are more widely dis-
tributed, so it is important to map both their distribution and quan-
tity as their actual levels of expression may be low.  
 Interestingly,  5-HT4 receptor splice variant expression has been 
shown to change dramatically in cancerous tissue. Normal adrenal 
tissue expressed both 5-HT4(a) and 5-HT4(b) and rarely 5-HT4(d)
splice variants while adrenocortical aldosterone producing adeno-
mas increased their expression of 5-HT4(d) and no longer expressed 
5-HT4(a) or 5-HT4(b) receptor splice variants [22]. These results indi-226    Current Neuropharmacology, 2007, Vol. 5, No. 4 Coupar et al. 
cate the importance of knowing both receptor expression patterns in 
normal and diseased tissue as there is the potential to modulate 
receptor function with splice variant selective drugs. 
Human 5-HT7 Receptor Splice Variants 
 The  5-HT7receptor was first cloned from human tissues in 1993 
[7]. Three human 5-HT7 splice variants were then discovered and 
named, h5-HT7(a), h5-HT7(b) and h5-HT7(d) that differ in their C 
terminal tails [36] (Fig. 2B). It was found that the brain and spleen 
contained relatively small amounts of 5-HT7(d) mRNA. However, 
h5-HT7(d) was reported later to be predominantly expressed in the 
human small intestine and colon together with a certain amount of 
the h5-HT7(d+5) fragment [43]. The known distribution of 5-HT7
receptor (or more prevalent) is summarised in Table 1.
THE C TERMINAL TAILS 
  All of the splice variants of both the h5-HT4 and h5-HT7 recep-
tors (except h5-HT4(h)) differ in the sequences of their intracellular 
(C-terminus) tails, but share an identical sequence up to Leu 358 for 
h5-HT4 and Leu 432 for h5-HT7 (see Fig. 2). This major portion 
contains the 7 transmembrane loops and the recognition site for 5-
HT.  
Differences in Agonist Potency 
  The C-terminal tails of 5-HT4 receptor splice variants have been 
found to directly influence their functional properties and this is 
most dramatically seen in their transduction of agonist responses. A 
notable example is renzapride, which is nearly 20 times more potent 
at the h5-HT4(d) than at the (g) splice variants in inducing cyclic 
AMP formation in COS cells. Another difference is that renzapride 
behaves as a full agonist at the h5-HT4(d), but is a partial agonist at 
the (g) variant [59]. One interpretation for this phenomenon is that 
the C-terminus regions exert different torsion forces on the con-
served transmembrane loops causing different steric presentations 
of the active site to its ligands. Some indirect support for this expla-
nation comes from our observation that the different splice variants 
exhibit over 10-fold variations in their affinities for ligands in bind-
ing studies (Coupar, Tochon-Danguy, Irving unpublished observa-
tions). Another explanation for the functional differences between 
5-HT4 splice variants is that they can link to different G proteins. 
Experiments using human embryonic kidney (HEK) cells have 
shown that the potencies of 5-methoxytryptamine at 5-HT4(a) and 5-
HT4(b) splice variants are different and that this is correlated to cou-
pling to only Gs and to Gi/o plus Gs proteins, respectively [63]. More 
recent experiments using adenoviral expression of h5-HT4(b) and 5-
HT4(d) splice variants in rodent cardiac myocytes that do not natu-
rally express 5-HT4 receptors demonstrated that the 5-HT4(d) recep-
tor was more efficiently coupled to adenylyl cyclase [23]. In addi-
tion, it was shown that pertussis toxin potentiated the stimulatory 
effect of 5-HT on L-type Ca
2+ current in rat myocytes expressing 
the 5-HT4(b) splice variant but not the 5-HT4(d) [23] providing fur-
ther support for the suggestion that the (b) splice variant couples to 
both Gs and Gi/o proteins. 
 5-HT7 receptors preferentially couple to adenylyl cyclase via
Gs [1] similar to 5-HT4 receptors. The screening of four agonists 
and a larger set of antagonists has so far failed to show any differ-
ences in binding affinities, potencies or efficacies at the three 
h5-HT7 splice variants [43,44]. However, with the discovery of an 
increasing number of 5-HT7 ligands (see [33] for review) this situa-
tion may change. A recent study, also using HEK 293 cells, has 
shown that the h5-HT7(d) splice variant exists in a greater internal-
ised state in the absence of agonist (5-carboxamidotryptamine) 
compared to the other two variants; h5-HT7(a) and h5-HT7(b). Inter-
Fig. (2). Serotonin receptor splice variants. (A). The 11 human 5-HT4 receptor splice variants. Most of the splice variants occur in the C terminal tail following 
the splice site coding for the amino acid leucine 358 (shown as first amino acid in each splice variant). However, splice variant h5-HT4(h) occurs in the second 
extracellular domain and has been reported to contain the “b” splice variant tail. (B). The 3 human 5-HT7 receptor splice variants which occur in the C terminal 
tail following the splice site at coding for the amino acid leucine 432 (shown as first amino acid in each splice variant). Potential phosphorylation sites (S/T) 
are in bold; and * indicates a PDZ ligand.
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estingly, the 5-HT7 antagonist, SB-269970, induced a partial trans-
location of the h5-HT7(d) variant from cytoplasm to plasma mem-
brane. Another noted difference was that the h5-HT7(d) variant was 
associated with a lesser efficacy at stimulating adenylyl cyclase. As 
a result, it was suggested that the C terminal tail of the h5-HT7(d)
splice variant, which is the longest of the three human splice vari-
ants, may contain a motif that interacts with cellular transport sys-
tems to limit the amount destined for the plasma membrane [34].  
  The ability of a ligand to provoke a GPCR-mediated response is 
measured in terms of ‘efficacy’ and the ligand is referred to as an 
‘agonist’ in classical pharmacological terms. It is now apparent that 
a balance occurs between the molecular mechanisms controlling 
receptor signalling, desensitisation and resensitisation or down 
regulation. Hence, the selectivity of agonists may be influenced by 
differences in the individual rates at which their splice variants 
desensitise and/or interact with numerous intracellular GPCR inter-
acting proteins (GIPs). 
Differences in Intracellular Signalling Modulated by GIPs 
  The most common GIPs interact with the C terminal tails of 
GPCRs; and PDZ domain containing proteins are the most abun-
dant members of this class. PDZ domains were first recognised as 
sequence repeats contained in three separate proteins: Post synaptic 
density (PSD) protein PSD-95, Discs large protein (the Drosophila
homologue) and tight junction protein ZO-1. PDZ proteins are in-
volved in scaffolding multi-protein complexes and have roles in 
protein trafficking (see [62] for a review). PDZ proteins bind to 
specific conserved consensus sequences that are found at the C-
terminal end of proteins. These consensus ligands have been classi-
fied as class I PDZ ligand of S/TX , class II of X and class III 
contains E/DX where  represents a hydrophobic residue and X 
any amino acid [62]. Many GPCRs express a PDZ ligand at the 
extremity of their C terminus (usually the last 3-4 amino acids). 
Thus the C terminal tail of GPCRs can contain a PDZ ligand at its 
extremity while residues upstream of the last 3-4 are important in 
modulating the specificity of interactions with other proteins [17]. 
An example of how different splice variant tails can influence pro-
tein interactions is depicted in Fig. (3). This example is based on 
results of proteomic studies on mouse brain where two 5-HT4 re-
ceptor splice variants with different PDZ ligands in the extremity of 
their C terminal tails were used as a bait ligand to isolate the inter-
acting proteins [42]. 
Fig. (3). Example of PDZ proteins interacting with mouse 5-HT4 receptor 
splice variants (a) and (e). The PDZ proteins, Veli, MPP3, NHERF and 
SNX27a interact with the extreme C-tail of 5-HT4(a) which contains the 
amino acids SCF. NHERF interacts with the scaffold protein ezrin and is 
involved in localising the 5-HT4(a) splice variant to specific parts of the 
membrane and SNX27a is involved at a later stage in assisting the receptor 
to be targeted to endosomes for desensitisation. The 5-HT4(e) receptor splice 
variant associates with nNOS, Sec23 and CIPP (another scaffolding pro-
tein). Arrows indicate protein interactions. For further details see text.
  Several serotonin receptors contain PDZ ligands at the extrem-
ity of their C-terminal tails and have been the focus of investiga-
tion. GIPs containing PDZ domains specifically regulate receptors 
in the serotonin receptor family. The 5-HT2A receptor contains a 
PDZ ligand at its extreme C terminus and directly binds to PSD-95 
which augments signal transduction and inhibits agonist-induced 
receptor internalisation [75]. Moreover, recent proteomic experi-
ments have demonstrated that the PDZ ligand of the 5-HT2A recep-
tor interacts with a different set of PDZ proteins to that of the 
5-HT2C receptor [12]. It is noteworthy that PSD-95 interacts with 5-
HT2A and 5-HT2C but not 5-HT4(a) receptors indicating that the dif-
ferent tails containing PDZ ligands interact with specific sets of 
proteins [12,42]. These specific sets of different PDZ proteins 
probably contribute to the different signal transduction properties of 
these receptors. Recently, another example of a GIP involved in 
serotonin receptor function has been reported where a small protein, 
p11, is involved in specifically transporting 5-HT1B receptors to the 
plasma membrane [69]. These findings provide support to the tenet 
that “specific sets of GIPs interact with different sets of receptor 
splice variants and that this is also tissue dependent”.  
  There are five 5-HT4 and one 5-HT7 receptor splice variants 
with canonical PDZ C-terminal extremity ligand binding sites (Fig. 
2). So far, there have been no reports on GIP interactions with any 
5-HT4 or 5-HT7 receptor splice variants in human tissue. However, 
a recent study identified 13 GIPs (mainly PDZ domain proteins) 
that interact with either the mouse 5-HT4(a) or 5-HT4(e) receptors 
[42]. Of these proteins, 10 interact specifically with the mouse 5-
HT4(a)receptorsplice variant. One of these is sorting nexin (SNX27) 
which is enriched in the brain and is involved in escorting the 5-
HT4(a) receptor splice variant to early endosomes for desensitisa-
tion. Another protein, NHERF appears to be involved in directing 
the 5-HT4(a) receptor to the microvilli region where the two proteins 
are co-localised with another protein called ezrin [42] that interacts 
with the membrane phosphatidylinositol-(4,5)-bisphosphate [9]. 
The 5-HT4(b) splice variant does not contain a PDZ domain (Fig. 
2A) and did not concentrate in the microvilli area. While the 5-
HT4(e) receptor splice variant co-localised with CIPP which is a 
scaffolding protein and importantly this was not seen with the 5-
HT4(b) receptor splice variant which does not contain a PDZ ligand 
[42]. These exciting results do indicate that the PDZ ligand domains 
of 5-HT4 or 5-HT7 receptor splice variants contribute to the receptor 
localisation and also suggest that rates of receptor desensitisation 
may vary with the splice variant expressed.  
Differences in Desensitisation Rate 
  The diversity in C-terminus sequences probably also contrib-
utes to the well known pharmacological fact that 5-HT induces 
desensitisation (tachyphylaxis) at different rates and magnitudes in 
different tissues. This natural phenomenon functions to limit the 
biological response to endogenous substances, such as 5-HT by 
uncoupling the GPCR from its signal transduction pathway (for 
reviews, see [30,57]). Desensitisation generally begins with ago-
nist-induced phosphorylation of the GPCR by GPCR receptor 
kinases (GRKs). The cytosolic proteins, arrestins then bind the 
phosphorylated GPCRs and prevent further coupling of that GPCR 
with G proteins and so reduce second messenger synthesis. The 
arrestin-GPCR complex is internalised by endocytosis where it can 
be recycled back to the membrane or degraded [30,57] (Fig. 4). 
GRKs play a critical role in GPCR desensitisation. There are three 
GRK subfamilies: rhodopsin kinase containing GRK1 and 7; 
adrenergicreceptor kinase (GRK2 and 3); and GRK4 group (GRK4, 
5 and 6). Both GRK2 and GRK5 can phosphorylate many GPCRs 
including 5-HT4 receptor splice variants [10] and GRK2 in particu-
lar is crucial for embryonic cardiac development [57]. The role of 
GRKs and receptor desensitisation has been the focus of many stud-
ies but their effects on serotonin receptors are less well docu-
mented.  228    Current Neuropharmacology, 2007, Vol. 5, No. 4 Coupar et al. 
Fig. (4). Process of GPCR desensitisation. (1). Activation and dissociation 
of G protein. (2). G recruits GPCR kinase (GRK) which phosphorylates 
the receptor. (3). Attachment of arrestin to GPCR (4). Internalisation of the 
arrestin – GPCR complex by endocytosis. (5). Dephosphorylated GPCR 
returns to the cell surface (resensitisation) or is degraded in the lysosome 
(down regulation).
  Desensitisation also has the potential to lessen the beneficial 
effects of agonists when used as therapeutic treatments. Indeed, we 
have established that desensitisation of native 5-HT4 receptors oc-
curs in vivo in the rat. We found that 5 day infusions of 5-HT (75 
g/kg per hour) induced rightward shifts of the 5-HT4 receptor-
mediated concentration-effect curves to 5-HT and the partial 5-HT4
agonist, SC 53116, in the oesophagus [55]. Therefore, knowledge 
of the extent and mechanisms of desensitisation in human tissue is 
crucial to the success of drug discovery programs aimed at develop-
ing 5-HT receptor agonists. In spite of this, only two studies have 
investigated the desensitisation properties of h5-HT4 receptor splice 
variants (human c and d variants [60]; mouse a, b, e, and f variants 
[10]) in cell culture. On the other hand, the h5-HT7 receptor splice 
variants all mediate heterologous desensitisation, which seems to be 
induced by both the agonist 5-HT and some antagonists [45]. In 
addition, all h5-HT7 receptor splice variants mediate heterologous 
desensitisation of endogenous Gs-coupled receptors in HEK 293 
cells through unknown mechanisms that are independent of cAMP 
dependent protein kinase activation [3,45]. 
CLINICAL RELEVANCE  
5-HT4 Receptors 
  More than 50 patents have been lodged since 2000 covering 
potential clinical applications for 5-HT4 agonists (ISI Web of 
Knowledge, Derwent Innovations Index, (http://portal.isiknowl-
edge.com/portal.cgi)). The claims are mainly for treatments of the 
digestive tract, notably irritable bowel syndrome (IBS), but also for 
gastroesophageal reflux disease (GORD), delayed gastric emptying 
and chronic constipation. The main rationale for these applications 
is that 5-HT4 receptors are distributed along the length of the diges-
tive tract, where their localisation on cholinergic nerves functions to 
enhance the release of acetylcholine. Localisation to smooth muscle 
cells also affects muscle tone. In the oesophagus, 5-HT4 receptors 
are thought to be located in the presynaptic nerve terminals of cho-
linergic interneurons and motor neurons [16], as well as the 
muscularis mucosa of the rat oesophagus, where they mediate 
relaxation directly [11]. In the intestines, 5-HT4 receptor activation  
was originally shown to enhance acetylcholine released in isolated  
preparations of the guinea-pig ileum [25-27]. Patents also cover   
treatment of CNS disorders, such as Alzheimer's disease, anorexia,  
drug dependence, migraine and pain. As in the digestive tract, 5- 
HT4 receptor function in the brain is to enhance the release of   
acetylcholine, but they also modulate the release of dopamine,   
GABA and 5-HT [8], hence the interest in 5-HT4 agonists for   
treatingcognitive disorders. Encouraging results have been obtained  
in rats, where the 5-HT4 agonist, RS 67333, improved associative  
memory and the 5-HT4 antagonist, RS 67532, decreased memory  
[52]. Their potential in the treatment of anorexia is suggested from 
experiments using obese mice which showed that the 5-HT4 ago-
nist, mosepride, improved food intake [4]. None of the patents 
claim the novel 5-HT4 receptor agonists are splice variant-selective, 
however, there are patents covering the DNA of splice variants 
themselves. One suggests gene therapy using the nucleic acid se-
quence of the 5-HT4(h) splice variant for gastrointestinal diseases, 
while another the 5-HT4(d) splice variant for treating cardiac and 
bladder disorders. Reference to Table 1 shows there is potential for 
refining drug selectivity because the target organs for these condi-
tions contain different combinations of splice variants. To date the 
digestive tract has received the greatest attention as an organ for 
treating various disorders using 5-HT4 agonists. Currently, these 
drugs are used to treat several types of motility disorders including 
gastro-oesophageal reflux disease (GORD). The most commonly 
used drugs were cisapride and metoclopramide, but cisapride has 
been virtually withdrawn (available on limited access) due to its 
ability to induce rare, but potentially fatal cardiac arrhythmias. Me-
toclopramide is a relatively old 5-HT4 agonist with significant affin-
ity at other receptor types. The most selective 5-HT4 agonist to date 
is tegaserod, which is used to treat IBS. Consequently, the rational 
for using tegaserod for the treatment of IBS is outlined next. 
Irritable Bowel Syndrome 
  It has been said that “A good set of bowels is worth more to a 
man than any quantity of brains” (Josh Billings, 1818–1885). Al-
though this quotation was intended to be humorous there is some 
truth which is illustrated by the symptoms of the irritable bowel 
syndrome (IBS), which is a common functional bowel disorder, 
associated with abdominal pain, sensations of bloating and altered 
bowel habit. Much research effort has focused on the serotonin-
modifying drugs to overcome dysfunction caused by perceived 
imbalance in either the amount of 5-HT released in the intestine or 
the expression of its receptors. This is because of the wealth of 
evidence showing that 5-HT alters the rate at which contents travel 
down the digestive tract and also the rate at which fluid is absorbed 
[31]. Consequently, 5-HT3 antagonists, 5-HT4 agonists and SSRI 
antidepressants have been the subject of intense investigation for 
the treatment of IBS [21,28]. For example, the 5-HT4 agonist, te-
gaserod, has been shown to reduce abdominal pain and give a de-
gree of relief from other symptoms in patients with constipation-
predominant IBS [61]. 5-HT4 receptors are present in several dis-
crete tissue locations in the human colon. These include the mucosa 
where the response to 5-HT released by enterotoxins induces Cl
-
secretion resulting in diarrhoea [19]. The 5-HT4 receptor is also 
present in the circular smooth muscle cells of the human colon [39]. 
5-HT4 agonists induce relaxation and inhibition of spontaneous 
contractions by activating adenylyl cyclase to increase intracellular 
levels of cAMP [53,54]. Paradoxically, 5-HT4 receptors expressed 
by cholinergic neurones in the human colon oppose the effect of 
this inhibitory postsynaptic 5-HT4 population by enhancing acetyl-
choline release [47]. The 5-HT receptors of cholinergic nerve end-
ings also function to enhance transmitter release to the longitudinal 
muscle bands (taenia coli) [66]. Consequently, it has been sug-
gested that the effects of 5-HT itself and 5-HT4 agonists to facilitate 
colonic propulsion are partly achieved by a coordinated combina-
tion of circular muscle relaxation and longitudinal muscle contrac-
tion [66]. Another less well established location of the 5-HT4 recep-
tor in the human colon is on sensory nerve endings, where its func-
tion may be to increase sensory perceptions arising from the abdo-
men leading to altered motility patterns. A recent clinical study 
lends some support to this hypothesis, which showed that IBS pa-
tients have significantly lower perception and defecation thresholds 
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matched control subjects [49]. The human small intestine and colon 
express various h5-HT4 splice variants (see Table 1, [13,15,56]). It 
is possible that different 5-HT4 receptor splice variants are ex-
pressed in the various locations and so contribute to the regulation 
of bowel functions in different ways. However, there is a lack of 
quantitative data for 5-HT4 receptor splice variant expression rela-
tive to the colon to substantiate such speculations.  
5-HT7 Receptors 
 5-HT7 receptors have also been identified in the circular muscle 
of the human colon, but as yet not in nerves [39,65]. All 5-HT7
receptor splice variants are expressed in the human small intestine 
and colon including a certain amount of the h5-HT7(d+5) fragment 
[43].  
  The patent literature also covers the potential use of novel full 
and partial 5-HT7 receptor agonists. The proposed applications are 
for the treatments of depression, anxiety and eating disorders, cor-
rection of circadian rhythm and migraine. As with the 5-HT4
ligands, none are suggested to be splice variant-selective. These 
applications are well-founded given the widespread distribution of 
the 5-HT7 receptor in the CNS and accumulating evidence for its 
functional effects. This includes the findings that some antidepres-
sants, such as amitriptyline, have relatively high affinities at the 5-
HT7 receptor (see [48,50,73] for reviews). The 5-HT7 receptor was 
originally discovered in the CNS where particularly high expression 
was found in the thalamus and hypothalamus. Functional studies of 
these areas led to the suggestion that 5-HT7 receptors localised in 
the suprachiasmatic nuclei of the hypothalamus are involved in 
controlling circadian rhythm [51]. Although subsequent studies 
have generated some uncertainty, it has been established that the 
selective 5-HT7 receptor antagonist, SB-269970 reduces paradoxi-
cal sleep in rats [35,48]. It has also been suggested that the 5-HT7
receptor is involved in migraine (see [70] for review). Several lines 
of evidence support this, such as the findings that the receptor is 
expressed in cranial blood vessels of experimental animals and that 
5-HT and 5-HT7-preferring agonists cause them to dilate. The tran-
script of the 5-HT7 receptor has been detected in human internal 
carotid and menigeal arteries, but functional evidence for its poten-
tial role in migraine is lacking. Other lines of evidence point to the 
involvement of the 5-HT7 receptor in hyperalgesic pain and neuro-
genic inflammation. The fact that prophylactic anti migraine 5-HT 
receptor antagonists have relatively high affinity for the 5-HT7 re-
ceptor further implicates this receptor in the abnormal vascular and 
neurogenic alterations that account for migraine headache.  
CONCLUDING REMARKS 
  The intricate differences in structural forms of 5-HT4 and/or 5-
HT7 splice variants suggest that they perform separate functions. 
This would have occurred over a long evolutionary period resulting 
in the refinement to the ancestral serotonin signalling system. Spe-
cific functions are also implied by the varying degrees of tissue-
specific distribution of most splice variants and that such functions 
are important to the organs in which they are expressed (Table 1)
and the disease state of the tissue. Refinement of function is con-
ferred by the C terminal tails of the splice variants which allow 
them to interact with different GIPs, GRKs and even different G 
proteins. To date, the established net outcome of splice variant-
specific interactions within the cell determine factors such as the 
rate, duration and intensity of the response to 5-HT. 
  Although it has been shown that some splice variants have 
different sensitivities to ligands, it has only been demonstrated with 
a small number of agonists. It remains a considerable challenge to 
identify and develop splice variant-selective drugs (no antagonists 
have yet been identified). However, the pressure to do so may 
increase as a result of the recent voluntary restriction of tegaserod 
to Special Access use only. This was necessary as IBS patients have 
been shown to experience a higher chance of cardiovascular events, 
such as heart attack, stroke, or severe heart-related chest pain. This 
predictable problem could be avoided if it were possible to discover 
an agonist with reasonable selectivity for a splice variant(s) present 
in the intestines, but not in the heart (e.g. 5-HT4(d or f)). Future drug 
discovery projects may also turn to the GIPs and GRKs in order to 
achieve tissue-specific effects.  
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